Abstract
Background. There is no standard formula to estimate doses for the intraperitoneal (IP) administration of carboplatin. We evaluated a combination of the Cockcroft and the Calvert (Cockcroft-Calvert) formula to determine the area under the curve (AUC) for IP carboplatin co-administered with intravenous (IV) cyclophosphamide (CPM). We also evaluated the correlation of carboplatin clearance determined by the Chatelut formula with carboplatin clearance determined by the Cockcroft-Calvert formula.
Methods. We performed a retrospective study of the records of 149 treatments in 30 patients who received IP carboplatin and IV CPM for ovarian carcinoma. The glomerular filtration rate was calculated with the Cockcroft formula. Carboplatin doses were determined based on the body surface area. The Cockcroft-Calvert formula was used to calculate the AUC. The Chatelut formula was also used to calculate the clearance of carboplatin and the AUC.
Results. The AUC calculated with the Cockcroft-Calvert formula was well correlated to the AUC calculated with the Chatelut formula (r 2 = 0.965). During the first four courses of IP carboplatin combined with IV CPM (300–500mg/m2), the correlation between the percent decrease in platelet count and the calculated carboplatin AUC varied among methods: Cockcroft-Calvert formula AUC:r 2 = 0.460; Chatelut formula AUC:r 2 = 0.431; body surface area dose:r 2 = 0.204; total dose:r 2 = 0.143.
Conclusion. To decrease patient platelet count by 67%, the optimal target AUC following IP administration of carboplatin in combination with 300–500mgCPM/m2IV was calculated as 6.5, using the Cockcroft-Calvert formula, and as 7.5, using the Chatelut formula. Considerable modification of the IP carboplatin dose is required after the fourth course. A prospective study is ongoing to confirm these results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Egorin MJ, Van Echo DA, Olman EA, et al. (1984) Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutane-dicarboxylato) platinum in patients with impaired renal function. Cancer Res 44:5432–5438
Calvert AH, Newell DR, Gumbell LA, et al. (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
Jodrell DI, Egorin MI, Canetta RM, et al. (1992) Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Chin Oncol 10:520–528
Childs WJ, Nicholls EJ, Horwiich A (1992) The optimization of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 3:291–296
Horwich A, Dearnaley DP, Jay NG, et al. (1991) Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol 9:62–69
Newell DR, Eeles RA, Gumbrell LA, et al. (1989) Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol 23:367–372
Reyno LM, Egorin MJ, Canetta RM, et al. (1993) Impact of CPM on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156–1164
Sorensen BT, Stromgren A, Jakobsen P, Jakobsen A (1991) Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:397–401
Fujiwara K, Yamauchi H, Sawada S, et al. (1992) The pharmacokinetics of intraperitoneal carboplatin (CBDCA) and dose-up study of intravenous cyclophosphamide in combination with intraperitoneal CBDCA for advanced ovarian cancer patients (in Japanese). Jpn J Cancer Chemother 19:2373–2379
Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by single injection method using51Cr-EDTA. Clin Sci 37:169–180
Chatelut E, Canal P, Brunner V, et al. (1995) Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573–580
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Rhodes PJ, Rhodes RS, McClelland GH, et al. (1987) Evaluation of eight methods for estimating creatinine clearance in men. Clin Pharm 6:399–406
Egorin MJ, Van Echo DA, Olman EA, et al. (1985) Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutane-dicarboxylato-platinum. Cancer Res 45:6502–6506
Taguchi J, Saijo N, Miura K, et al. (1987) Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. Jpn J Cancer Res 78:977–982
Calvert AH, Newell DR (1993) Carboplatin pharmacokinetics/clinical dosing. Bristol-Myers Squibb, Princeton
Alberts DS, Liu PY, Hannigan EV, et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Fujiwara, K., Yamauchi, H., Yoshida, T. et al. Relationship between calculated carboplatin area under the curve, using the Cockcroft-Calvert formula and the Chatelut formula, and thrombocytopenia induced by intraperitoneal carboplatin in combination with intravenous cyclophosphamide. Int J Clin Oncol 3, 304–310 (1998). https://doi.org/10.1007/BF02628051
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02628051